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Abstract
Tendon is a commonly injured soft musculoskeletal tissue, however, poor healing potential and ineffective treatment
strategies result in persistent injuries and tissue that is unable to perform its normal physiological function. The
identification of a stem cell population within tendon tissue holds therapeutic potential for treatment of tendon
injuries. This study aimed, for the first time, to characterise and compare tenocyte and tendon-derived stem cell
(TDSC) populations in murine tendon. Tenocytes and TDSCs were isolated from murine tail tendon. The cells were
characterised for morphology, clonogenicity, proliferation, stem cell and tenogenic marker expression and
multipotency. TDSCs demonstrated a rounded morphology, compared with a more fibroblastic morphology for
tenocytes. Tenocytes had greater clonogenic potential and a smaller population doubling time compared with TDSCs.
Stem cell and early tenogenic markers were more highly expressed in TDSCs, whereas late tenogenic markers were
more highly expressed in tenocytes. Multipotency was increased in TDSCs with the presence of adipogenic
differentiation which was absent in tenocytes. The differences in morphology, clonogenicity, stem cell marker
expression and multipotency observed between tenocytes and TDSCs indicate that at least two cell populations are
present in murine tail tendon. Determination of the most effective cell population for tendon repair is required in
future studies, which in turn may aid in tendon repair strategies.
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Background
Tendon is prone to injury and degeneration, and this is
most often seen in occupational and sporting environ-
ments [1–3]. The healing process for tendon is poorly
understood, however it is well documented that tendon
tissue is unable to heal effectively resulting in painful and
debilitating scar tissue, which is unable to perform its nor-
mal physiological function [1, 4]. The current treatment
options for damaged or degenerated tendon vary depend-
ing on the severity and location of the tendinopathy [5–8]
and include physiotherapy; pharmacotherapies, such as
anti-inflammatories; corticosteroid injections; or surgery
[5, 6, 9]. However, these treatment strategies are largely
ineffective [5]; therefore, an alternative approach for the
management and treatment of tendinopathies is currently
being sought.
Tenocytes are tendon-specific fibroblasts and trad-
itionally were thought to be the only cell type present in
tendon, however it is now thought that tenocytes
account for approximately 95% of the cellular content of
tendon, with progenitor cells, endothelial cells and chon-
drocytes comprising the remaining 5% [10]. Tenocytes
are located between collagen fibrils and in the interfasci-
cular matrix and they are responsible for the production
of the ECM as well as the repair and maintenance of
tendon tissue [10, 11]. The identification of a stem cell
population within tendon tissue [12] holds therapeutic
potential for treatment of tendon injuries. Tendon-
derived stem cells (TDSCs) have been shown to be
clonogenic, multipotent and express stem cell and
tenogenic markers [12–15].
A number of tissue engineering strategies have utilised
TDSCs for tendon repair with some successful outcomes
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[16–20]. These studies highlight the potential use of
TDSCs in tendon repair strategies, however further
characterisation of TDSCs is necessary; particularly, the
identification and characterisation of different cell popu-
lations within tendon tissue. Comparisons of tendon cell
populations are lacking in the literature with only two
studies comparing tenocytes and TDSC properties in the
rabbit [14] and the horse [15]. These two studies
reported conflicting results with large differences found
between tenocyte and TDSC populations in the rabbit
[14], but few differences observed in the horse [15]. No
studies, to date, have compared tendon cell populations
in rodents, despite the plethora of research on TDSCs in
rats and mice.
This study aimed to isolate, characterise and compare
tenocytes and TDSCs from murine tail tendon. We
hypothesised that tenocytes would demonstrate pheno-
typic differences when compared with TDSCs, particu-
larly differences in stem cell properties.
Methods
Isolation of murine tenocytes and TDSCs
HuR floxed embryos were obtained from Dimitris
Kontoyiannis, Alexander Fleming Research Centre,
Greece [21] and crossed with Aggrecan A1 Cre mice
obtained from George Bou-Gharios, University of
Liverpool, UK [22]. Tendon tissue was extracted from the
tails of 6–8 week old C57BL/6 mice (HuRfl/flAcan-Cre+/−)
which were euthanased for reasons unrelated to this
study, and digested for 3 h at 37 °C in 20 ml 375 U/ml
collagenase type I and 0.05% trypsin. The resulting cell
suspension was strained and then centrifuged at 1200 g
for 10 min and the supernatant discarded. The cells were
resuspended in complete DMEM (DMEM supplemented
with 20% foetal calf serum, 100 U/ml penicillin, 100 μg/ml
streptomycin and 2 μg/ml amphotericin B) and counted
using a haemocytometer. For tenocyte isolation the cells
were seeded at 1 × 105 cells in T25 culture flasks (4 × 103
cells/cm2) [23, 24] and for TDSC isolation the cells were
seeded at 100 cells per well of a 6-well plate (10 cells/cm2)
[13, 15, 16, 25–28]. All cells were cultured in complete
DMEM at 37 °C, 5% CO2 and 21% O2. TDSCs were
cultured for 6–8 days before passaging, whereas tenocytes
were cultured for 2–3 days, cells were split 2:1 for
subsequent passages. For TDSCs colonies were isolated
using cloning cylinders and local application of 0.05%
trypsin. All cells were analysed at passage 2–3 [15].
Cell proliferation assay
Cells at passage 2 were seeded at 10,000 cells in T25
culture flasks at day 0. At 80% confluency the cells were
counted and the doubling time calculated using the
formula below:
(LOG10(cell number after proliferation)-LOG10(initial
seeding density))/LOG10(2) [29].
Colony formation assay
Cells at passage 2 were seeded at 100 cells/cm2 in 6-well
cell culture plates. After 7 days in culture the cells were
washed and then fixed with 6% gluteraldehyde and
stained with 0.5% crystal violet solution [30]. The cells
were washed again and imaged using a biomolecular
imager (Typhoon FLA 7000, GE Healthcare) and
analysed using ImageQuant software (GE Healthcare)
for colony number and size.
Tri-lineage differentiation assays
Cell monolayers were cultured for 21 days in osteogenic
(complete DMEM containing 100 nM dexamethasone,
10 mM β-glycerophosphate and 50 mM ascorbic acid)
[31] and adipogenic (complete DMEM containing 1 μM
dexamethasone, 100 μM indomethacin, 10 μg/ml insulin
and 500 μM IBMX) [32] induction media. Cell pellets
(containing 5 × 105 cells) were cultured for 21 days in
chondrogenic (complete DMEM containing 100 nM
dexamethasone, 25 μg/ml ascorbic acid, 10 ng/ml
TGF-β3 and ITS+ 3 supplement) [33] induction
media. Control cells for all treatments were cultured
in complete DMEM. After culturing, the cells were
stained with alizarin red and alkaline phosphatase to
assess osteogenic differentiation, Oil Red O to assess
adipogenic differentiation, or alcian blue for chondro-
genic differentiation, as described in the PromoCell
MSC application notes (http://www.promocell.com/
downloads/application-notes/). Chondrogenic pellets
were also paraffin embedded and 4 μm sections taken
which were rehydrated and further stained with 1%
Alcian blue solution and 0.1% Safranin O solution. In
addition, separate cell pellets were digested in 10 U/ml pa-
pain solution for 3 h at 60 °C before the total sulphated
glycosaminoglycan (sGAG) content was quantified.
Dimethylmethylene blue dye was added to each sample
and the absorbance read immediately at 570 nm. The
sGAG content was calculated from a standard curve pro-
duced using chondroitin sulphate standards [34]. RNA
was extracted from all assays to analyse lineage-specific
gene expression.
RNA extraction and quantitative real time-polymerase
chain reaction (qRT-PCR)
RNA was extracted from all cell types by firstly applying
Trizol to cell monolayers and using a cell scraper for cell
detachment. After vortexing and centrifugation, 50 μg/ml
glycoblue and 100% isopropanol were added to the
aqueous phase for RNA precipitation. After centrifuga-
tion, the pellets were washed in 75% ethanol and resus-
pended in Tris-EDTA buffer. The quantity and quality of
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RNA was assessed using a NanoDrop spectrophotometer
(Thermo Fisher). 4 U DNase was then added to the sam-
ples to remove DNA, after which time an equal volume of
phenol:chloroform:IAA was added to each sample. The
RNA was then precipitated, centrifuged, washed in etha-
nol and the RNA quality assessed. cDNA was synthesised
in a 25 μl reaction from 1 to 2 μg of total RNA. The con-
ditions for cDNA synthesis were: incubation at 5 min at
70 °C, 60 min at 37 °C and 5 min at 93 °C with M-MLV
reverse transcriptase and random-hexamer oligonucleo-
tides (Promega) [35, 36].
qRT-PCR was conducted using a GoTaq(R) qPCR
Master Mix (Promega), and in a 25 μl reaction 10 ng of
cDNA was amplified in an AB 7300 Real Time PCR Sys-
tem (Applied Biosystems). After an initial denaturation
for 10 min at 95 °C, 40 PCR cycles were performed con-
sisting of 15 s at 95 °C and 1 min at 60 °C. Relative gene
expression was calculated according to the comparative
Ct method [35–37]. Murine specific primers were used
(Table 1) and GAPDH was used as an internal control.
Primers were designed using Primer-BLAST (NCBI),
and the quality of each primer was tested using NetPri-
mer (Premier Biosoft). In addition, each primer was sub-
jected to a BLAST (NCBI) search to ensure specificity.
The best housekeeping gene was determined using the
geNorm algorithm [38] and all primers were tested for
efficiency; efficiencies between 90 and 110% were
deemed to be acceptable.
Statistical analysis
Statistical analysis was performed using SPSS (IBM) and
SigmaPlot (Systat Software Inc). To ensure data was nor-
mally distributed Shapiro Wilk tests were performed. For
normally distributed data parametric tests were used for
pairwise comparisons. For data which was not normally
distributed Log10 data transformations were performed
resulting in normally distributed data. For pairwise com-
parisons paired or independent Student’s t-tests were
used. P-values ≤0.05 were taken to be significant.
Results
Tenocyte and TDSC morphology and colony formation
Tenocytes and TDSCs demonstrated varying cell
morphologies; tenocytes were large, flat and fibroblas-
tic, whereas TDSCs were smaller and more rounded
(Fig. 1a).
Both cell types were able to form colonies, however
these colonies were not homogeneous. Tenocytes gener-
ally formed large sparse colonies, whereas TDSCs
formed more compact, dense colonies. When quantified
Table 1 Primer sequences for murine genes
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tenocytes produced significantly more colonies than
TDSCs (Fig. 1b), however colony size was similar
between cell types (Fig. 1c).
Tenocyte and TDSC proliferation
Both tenocytes and TDSCs proliferated very slowly and
demonstrated very long population doubling times
(PDT) with a mean (± SD) of 354 (±140) and 508 (±49)
hours respectively (Fig. 2).
Tenocyte and TDSC marker expression
The gene expression of stem cell and tenogenic markers
was assessed by qRT-PCR (Fig. 3). The majority of stem
cell (Nanog and CD73) and early tenogenic markers
(scleraxis and Mohawk) were more highly expressed in
TDSCs when compared with tenocytes, whereas markers
found in developed tendon (tenascin C, thrombospondin-
4 and tenomodulin) exhibited higher expression in teno-
cytes compared to TDSCs. Expression of Nanog, scleraxis
and Mohawk was significantly increased in TDSCs com-
pared with tenocytes. Tenomodulin expression was sig-
nificantly increased in tenocytes compared with TDSCs.
The stem cell markers Sca-1 and CD90 were similarly
expressed in both cell types. The haematopoietic stem cell
marker CD45 demonstrated low expression with signifi-
cantly higher levels observed for tenocytes compared with
TDSCs.
Tenocyte and TDSC tri-lineage differentiation capacity
The ability of tenocytes and TDSCs to differentiate into
different cell lineages was analysed by staining, glycos-
aminoglycan (GAG) assays and qRT-PCR for gene
expression analysis.
Both cell types demonstrated osteogenic differentiation
as assessed by alkaline phosphatase levels and alizarin
a b
c
Fig. 1 Tenocyte and TDSC morphology and colony formation. Representative images of cell morphology are shown, bars = 100 μm (a). Colonies
were counted (b) and measured (c) using ImageQuantTL software. Error bars shown represent SD. Pairwise comparisons were performed using a
Student’s independent t-test. ap = 0.01. n = 4 biological replicates
Fig. 2 Population doubling time for tenocytes and TDSCs. Error bars
shown represent SD. Pairwise comparisons were performed using a
Student’s independent t-test. n = 4 biological replicates
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red staining (Fig. 4). No adipogenic differentiation was
observed for tenocytes, however oil red O staining was
seen in differentiated TDSCs (Fig. 4). Tenocytes demon-
strated some chondrogenic differentiation, with an
increase in pellet size and intensity of safranin O stain-
ing in positive samples (chondrogenic induction media)
compared with negative samples (control media). Due to
low cell numbers, it was not possible to undertake
chondrogenic differentiation assays on TDSCs (Fig. 4).
There was an increase in mean sGAG formation for
tenocytes from 0.25 (±0.3) μg in negative samples to 0.5
(±0.54) μg in positive samples, however this was not
significant. sGAG content was not analysed in TDSCs
due to low cell numbers (Fig. 5).
Gene expression analysis of lineage specific genes
showed a significant increase in the expression of osteo-
genic markers RUNX2 (runt-related transcription factor 2)
and OPN (osteopontin) for TDSCs, however expression in
tenocytes was similar between negative and positive sam-
ples (Fig. 6). There were small increases in all adipogenic
Fig. 3 Gene expression analysis of stem cell markers in tenocytes
and TDSCs. Values are shown on a logarithmic scale and normalised
to GAPDH. Error bars shown represent SD. Pairwise comparisons
were performed using independent Student’s t-tests after Log10
transformation of data. ap = 0.009, bp = 0.011, cp = 0.001, dp = 0.011,
ep = 0.011, fp = 0.011. n = 6 biological replicates
Fig. 4 Histological analysis of tri-lineage differentiation potential of tenocytes and TDSCs. Representative images are shown for both cell types
after induction of osteogenic, adipogenic and chondrogenic differentiation (positive) and also for control samples (negative), after appropriate
staining. Cells subjected to osteogenic differentiation media were stained for both alkaline phosphatase (ALP) activity and calcium deposits using
alizarin red (AR). Cells subjected to adipogenic differentiation media were stained for oil droplet formation using oil red O (ORO), and cell pellets
exposed to chondrogenic differentiation media, for GAG formation using alcian blue (AB) and safranin O (SO). Bar = 100 μm. Chondrogenic
staining was not performed on TDSCs due to low cell numbers. n = 6 biological replicates
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marker genes, such as LEPTIN, FABP4 (fatty acid binding
protein 4) and PPARγ (peroxisome proliferator-activated
receptor gamma), for tenocytes, and much larger signifi-
cant increases for TDSCs in positive samples compared to
negative samples (Fig. 6). Similarly, there was an increase
in the majority of chondrogenic markers, such as AGG
(aggrecan) and COL2 (collagen type II) in positive samples
compared with negative samples for tenocytes although
these were not significant. Chondrogenic markers were not
analysed in TDSCs due to low cell numbers (Fig. 6).
Discussion
In this study we have isolated a population of cells in
murine tendon that possess some of the traditional
hallmarks of a stem cell: the ability to form colonies, the
expression of stem cell markers and multipotency [39].
These findings are consistent with the published litera-
ture on murine TDSCs [12, 40–42]. The only discrep-
ancy is the extended population doubling time observed
in this study compared with previous reports. This could
be explained by variations in cell isolation procedures. In
this study we selected a low cell seeding density based
on previous work in our group [15] and other studies
[13, 16, 25–28], however some previous studies have
used higher seeding densities. Alternatively, these differ-
ences may be due to mouse strain variation as research
on murine mesenchymal stem cells (MSCs) has noted
considerable variation in stem cell properties, including
proliferation, between different strains of mice [43]. In
addition, phenotypic differences of MSCs have been
observed within certain strains of mice [44], highlighting
the biological variation in murine stem cell populations.
The TDSCs isolated in this study also stopped expanding
at early passages which made certain assays impossible
to perform due to low cell numbers. This may be due to
stem cell quiescence, senescence or terminal differenti-
ation and could indicate that these cells are not in fact
stem cells but a progenitor cell population. For this rea-
son we were unable to perform chondrogenic differenti-
ation assays on TDSCs. We observed only moderate
levels of chondrogenic differentiation for tenocytes
which were low compared to reports in human tendon
cells [45] and murine tendon tissue [46]. It is likely that
the chondrogenic differentiation potential of TDSCs
would be increased compared to tenocytes, as seen for
osteogenic and adipogenic differentiation.
To our knowledge, no studies have compared the
phenotype of murine tenocytes and TDSCs and we ob-
served a number of phenotypic differences between
these two cell populations. Tenocytes and TDSCs
demonstrated different cell morphologies and colony
forming ability as well as differences in the expression of
certain stem cell markers, and some differences in multi-
potency. TDSCs generally conformed to the criteria of
MSCs, as specified by the International Society for
Cellular Therapy [39] (although chondrogenic potential
could not be confirmed), whereas tenocytes did not due
to a lack of adipogenic differentiation. The primary simi-
larity between tenocytes and TDSCs was the expression
of tenogenic markers such as tenascin C and thrombos-
pondin 4, which was expected given that both cell popu-
lations were derived from tendon tissue. No studies have
previously compared murine tenocytes and TDSCs,
however such a comparison has been performed in other
species [14, 15]. Our previous work demonstrated no
discernible differences between tenocyte and TDSC
populations in equine superficial digital flexor tendon,
however a restricted differentiation potential was ob-
served for equine TDSCs [15]. In contrast, a comparison
of tenocytes and TDSCs in rabbit Achilles and patellar
tendon demonstrated considerable differences in stem-
ness between the two cell populations [14], which are
more consistent with our study. The phenotypic differ-
ences observed in this study between tenocytes and
TDSCs suggest that these cells are distinct populations
with differing properties.
TDSCs have been used in a number of tissue engin-
eering strategies to promote tendon healing with
some encouraging results in human and animal
models [16–20, 47, 48]. However, many of these stud-
ies do not state the exact TDSC isolation method
used, or use varying cell seeding densities; in addition,
many studies have not fully characterised the cells
used for tendon repair. Therefore, it is possible that
different tendon cell populations have been used
across studies, which were not always defined as
TDSCs. It is necessary to determine which tendon
Fig. 5 Total sulphated glycosaminoglycan (sGAG) content of cell
pellets with (positive) or without (negative) chondrogenic induction.
Error bars shown represent SD. Pairwise comparisons were performed
using paired Student’s t-tests. sGAG content was not measured for
TDSCs due to low cell numbers. n = 6 biological replicates
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cell population is most effective for tendon repair.
The increased stemness of murine TDSCs may pro-
mote tendon repair, however the poor proliferative
potential of these cells is not conducive to tendon re-
generation. Alternatively, murine tenocytes which
demonstrated improved proliferative potential may
provide a more suitable cell population for tendon re-
generation. It is possible that the restricted differenti-
ation potential of tenocytes may actually provide a
therapeutic benefit during tendon healing by avoiding
aberrant differentiation. Analysis of different tendon
cell populations in human tendon has not yet been
performed, however the presence of multiple tendon
cell populations in several species [14, 15] would sug-
gest the presence of more than one tendon cell
population in human tendon. A comparison of tendon
cell populations in humans is warranted, as well as
investigation of the therapeutic potential of different
tendon cell populations in vivo, which may highlight
alternative, more effective tendon cell populations for
human tendon repair strategies.
Conclusion
In conclusion, we have isolated and characterised two
distinct tendon cell populations from murine tail tendon
with differential properties. These tendon cell popula-
tions may provide therapeutic benefit for tendon injury
and determination of the most effective cell population
for tendon regeneration strategies in both humans and
animals requires further investigation.
Fig. 6 Gene expression analysis of lineage specific markers for murine tenocytes and TDSCs. Values are shown on a logarithmic scale and normalised
to GAPDH. Error bars shown represent SD. Pairwise comparisons were performed using paired Student’s t-tests after Log10 transformation of data.
ap = 0.021, bp = 0.02, cp = 0.021, dp = 0.021, ep = 0.021. Chondrogenic marker genes are not shown for TDSCs due to low cell numbers. n = 6
biological replicates
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